drugset
drugset / Trial / NCT06332014

Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China

NCT06332014 ↗

Phase 4 Active not recruiting 102 enrolled Amgen
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate the efficacy of Prolia on lumbar spine BMD at 12 months.

Timeline

Start
2024-08-06
Primary completion
2027-01-23
Completion
2027-01-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Denosumab Monoclonal antibody — Subcutaneous

Indications

osteoporosis